

Potential of Volatile Anesthetics in Organ Transplantation

ISAP 2018, San Fransisco

Gertrude Nieuwenhuijs-Moeke, MD,
Dept. of Anesthesiology, UMCG



Disclosures


Vapor-2 is funded by:

- The Astellas European Foundation Transplantation Grant 2014
- Astellas Pharma
- Baxter/ESA grant on improvement of perioperative outcome 2017



Perioperative medicine

- Surgical care: operation and the disease being treated with this operation
- Grocott-Pearse BJA 2012¹: Response to surgery is the primary disease process and the consequent organ dysfunction the condition to focus on
- Khuri Ann Surg 2005²: 105,951 patients, 8 different procedures
 - Most important determinant of long-term survival: occurrence of 1 of the 22 predefined postoperative complications first 30 days after surgery.



- Intra-operative interventions reduce incidence of postoperative complications

1. Grocott MP, Pearse RM. Perioperative medicine: the future of anaesthesia? *Br J Anaesth.* 2012; 108(5):723-6
 2. Khuri SF, Henderson WG, DePalma RG et al. Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. Participants in the VA National Surgical Quality Improvement Program. *Ann Surg* 2005; 242:326-41


Pleiotropic effects anesthetics

- Effects other than providing general anesthesia
- Not new
 - Gaylord/Simpson 1911
 - Graham 1916
- Increased interest in choice of anesthetics and outcome of the patient
 - Cognitive effects
 - Immunomodulation
 - **Ischemia and reperfusion injury (IRI)**



UMCG Transplantation
Comprehensive Transplant Center

Ischemia



Nieuwenhuijs-Moeke G.J. Peroperative renal protective strategies in kidney transplantation, PhD thesis, 2018



UMCG Transplantation
Comprehensive Transplant Center

Ischemia:

Cell damage - Cell death


What happens when you turn on the oxygen....



Ischemia



Reperfusion




Reperfusion:

More cell damage - cell death

UMCG Transplantation
Comprehensive Transplant Center

10



Anesthetic conditioning

- Ability of anesthetic agents to induce biochemical changes that may attenuate IRI
- Pre-, per-, postconditioning
- Mostly described for volatile anesthetics (VA)
- Trifluorohalogenated carbon (CF₃) groups¹
- Mechanism complex, multiple pathways involved

Sevoflurane

1. Urner M, Limbach LK, Herrmann IK, et al. Fluorinated groups mediate the immunomodulatory effects of volatile anesthetics in acute cell injury. Am J Respir Cell Mol Biol 2011; 45:617-24

UMCG Transplantation
Comprehensive Transplant Center

12

The potential of volatile anesthetics

13

Prevention opening mPTP


Nieuwenhuijs-Moeke G.J. 2018. Adapted from: Andrews DT, Royse C, Royse AG. The mitochondrial permeability transition pore and its role in anaesthesia-triggered cellular protection during ischaemia-reperfusion injury. *Anaesth Intensive Care*. 2012 Jan;40(1):46-70

14

The potential of volatile anaesthetics

Cell death programs

Endothelial dysfunction




UMCG Transplantation
Comprehensive Transplant Center

15

Protection of the glycocalyx

- In vitro and in vivo animal experiments^{1,2}
- Pre and post conditioning effective
- ↓ level of extravasation of fluid
- ↓ levels of syndecan-1, heparan sulfate, hyaluronan
- ↓ adhesion of leucocytes/platelets
- Preserved integrity

A




vascular lumen
glycocalyx }
endothelial cell
0.1 μm

I/R

→

B




vascular lumen
glycocalyx }
endothelial cell
0.1 μm

I/R+ sevo

→

C




vascular lumen
glycocalyx }
endothelial cell
0.1 μm

- Proposed mechanism: ↓ release cathepsin B



1. Annecke T, Chappell D, Chen C et al. Sevoflurane preserves the endothelial glycocalyx against ischemia-reperfusion injury. *Br J Anaesth.* 2010; 104(4):414-21

2. Chappell D, Heindl B, Jacob M et al. Sevoflurane reduces leukocyte and platelet adhesion after ischemia-reperfusion by protecting the endothelial glycocalyx. *Anesthesiology.* 2011 Sep;115(3):483-91.



UMCG Transplantation
Comprehensive Transplant Center

16



VA and cells of the innate immunesystem

- **Neutrophils**
 - ↓ cellular function
 - ↓ ROS production
 - ↓ expression of endothelial adhesion molecules and ↓ adhesion to endothelium
 - ↓ tissue infiltration
- **Monocytes/Macrophages**
 - ↓ number
 - ↓ release proinflammatory cytokines IL-1 β , TNF- α , IL-6, IL-8
 - ↑ expression iNOS and NO production
 - Influence on APC function unknown
- **Natural Killer cells**
 - ↓ cytotoxicity
 - ↓ release proinflammatory cytokines
- **Dendritic cells**
 - Effect unknown

1. Yuki K, Eckenhoff RG. Mechanisms of the Immunological Effects of Volatile Anesthetics: A Review. *Anesth Analg*. 2016; 123(2):326-35
2. Stollings LM, Jia LJ, Tang P et al. Immune Modulation by Volatile Anesthetics. *Anesthesiology*. 2016; 125(2):399-411
3. Sedghi S, Kutscher HL, Davidson BA et al. Volatile Anesthetics and Immunity. *Immunol Invest*. 2017; 46(8):793-804
4. Kurosawa S, Kato M. Anesthetics, immune cells, and immune responses. *J Anesth*. 2008;22(3):263-77



UMCG Transplantation
Comprehensive Transplant Center

19

VA and cells of the adaptive immune system

- **T cells**
 - ↓ number and proliferation
 - ↓ Th1/Th2 ratio
 - Induction apoptosis
 - ↓ release proinflammatory cytokines
 - ↓ adhesion molecules
- **B cells**
 - ↓ number
 - Induction B cell injury
- **Tregs**
 - Effect unknown

1. Yuki K, Eckenhoff RG. Mechanisms of the Immunological Effects of Volatile Anesthetics: A Review. *Anesth Analg*. 2016; 123(2):326-35
2. Stollings LM, Jia LJ, Tang P, Dou H, Lu B, Xu Y. Immune Modulation by Volatile Anesthetics. *Anesthesiology*. 2016; 125(2):399-411
3. Sedghi S, Kutscher HL, Davidson BA, Knight PR. Volatile Anesthetics and Immunity. *Immunol Invest*. 2017; 46(8):793-804
4. Kurosawa S, Kato M. Anesthetics, immune cells, and immune responses. *J Anesth*. 2008;22(3):263-77





UMCG Transplantation
Comprehensive Transplant Center

20


Lymphocyte Function-associated Antigen-I inhibition

- LFA-1, integrin adhesion molecule, expressed on all leukocytes
- Activated by chemokines or antigens
- Ligand: ICAM-1, expression ↑ upon I/R
- LFA-1-ICAM-1 interaction
 - ICAM-1 endothelium: leucocyte transmigration
 - ICAM-1 target cell: activation NK cell, lysis target cell
 - ICAM-1 APC: T cell activation
- Lovastatin binding site, inactive state
- In vitro at clinically relevant concentrations
- Also described for propofol (supranormal concentrations)
- Blockade of LFA-1 is recognized as a potential target to reduces allograft rejection²




1. Yuki K, Astrof NS, Bracken C, Soriano SG, Shimaoka M. Sevoflurane binds and allosterically blocks integrin lymphocyte function-associated antigen-1. *Anesthesiology*. 2010;113:600-9
 2. Nicolls MR, Coulombe M, Yang H, Bolwerk A, Gill RG. Anti-LFA-1 therapy induces long-term islet allograft acceptance in the absence of IFN-gamma or IL-4. *J Immunol*. 2000; 164(7):3627-34

The potential of volatile anaesthetics



Transcriptional reprogramming



Nieuwenhuijs-Moeke G.J. *Peroperative renal protective strategies in kidney transplantation*, PhD thesis, 2018



UMCG Transplantation
Comprehensive Transplant Center

23

Upregulation of HIF

- VA are able to upregulate HIF1 α ,2 α
- Possibly via the PI3K/Akt-mTOR pathway
- 15 minutes sevoflurane post conditioning isolated hearts¹:
 - Upregulation HIF-1 α
 - Improved myocardial function
 - Results abolished with 2-methoxyestradiol
- Preconditioning renal I/R model rat²:
 - Lower BUN/creatinin levels
 - Higher HIF-2 α expression
 - Effect abolished in HIF-2 α knock out mice
- Propofol inhibits HIF-1 α production

1. Yang L, Xie P, Wu J et al. Sevoflurane postconditioning improves myocardial mitochondrial respiratory function and reduces myocardial ischemia-reperfusion injury by up-regulating HIF-1. *Am J Transl Res.* 2016; 8(10):4415-24
2. Zheng B, Zhan Q, Chen J et al. Sevoflurane pretreatment enhance HIF-2 α expression in mice after renal ischemia/reperfusion injury. *Int J Clin Exp Pathol.* 2015; 8(10):13114-9




UMCG Transplantation
Comprehensive Transplant Center

24


In conclusion

- VA interfere with many of the processes underlying the pathophysiology of IRI
- Potentially protective effect against IRI
- Effects are dose, timing and context dependant
- Clinical studies are needed




Kidney transplantation

- IRI inevitable in transplantation
- Consequences of IRI:
 - Delayed graft function (DGF)
 - Primary non function (PNF)
 - Acute rejection (AR)
 - IFTA and Graft loss
 - Influence on short and long term graft outcome
- DGF
 - Increased morbidity,
 - Patients anxiety,
 - Prolonged hospitalization
 - Additional diagnostic procedures and costs



Badet L, Codas R, Barrou B, Hauet T
 Department of Kidney and pancreas Transplantation, Lyon France
 On behalf of the FLIRT Group Fédération pour l'étude des lésions d'ischémie reperfusion en transplantation



Anesthetic conditioning kidney

- Rats anesthetised with VA and subjected to renal I/R showed¹
 - reduced levels of plasma creatinine and cytokines,
 - reduced proinflammatory leucocyte infiltration
 - reduced histological renal necrosis
- Mice, anesthetised with isoflurane and subjected to renal I/R²
 - reduction of neutrophil, macrophage and lymphocyte infiltration
- No clinical data

1. Lee HT, Ots-Settik A, Fu Y et al. Differential protective effects of volatile anesthetics against renal ischemia–reperfusion injury in vivo. *Anesthesiology* 2004; 101:1313–24

2. Lee HT, Kim M, Kim M, et al. Isoflurane protects against renal ischemia and reperfusion injury and modulates leukocyte infiltration in mice. *Am J Physiol Renal Physiol* 2007; 293: F713–22



UMCG Transplantation
Comprehensive Transplant Center

29

VAPOR

- **V**(olatile) **A**(naesthetic) **P**(rotection) **O**(f) **R**(enal) transplants trial
- 2-step study
- Difference in renal protective effect of two representative methods of anaesthesia in kidney transplantation.
 - TIVA: propofol-remifentanil based anesthesia
 - Sevoflurane-remifentanil based anesthesia.



UMCG Transplantation
Comprehensive Transplant Center

VAPOR-1

- Prospective, single blind, randomized controlled trial
- Living donor kidney transplantation
 - Homogenous model of IRI
 - Reproducible ischemia times
 - Possibility to treat the donor
- Proof of concept
- a sevoflurane based anesthesia is able to induce AC and thereby reduces post-transplant renal injury reflected by a reduced release of kidney injury biomarkers compared to a propofol based anesthesia

Nieuwenhuijs-Moeke GJ, Nieuwenhuijs VB, Seelen MAJ et al. Propofol-based anaesthesia versus sevoflurane-based anaesthesia for living donor kidney transplantation: results of the VAPOR-1 randomized controlled trial. *Br J Anaesth.* 2017 May 1;118(5):720-732



UMCG Transplantation
Comprehensive Transplant Center

VAPOR-1

- Donor and recipient coupled and randomised to one of the three groups:
 - **PROP**: **PROP**ofol maintenance; 20 couples=40 patients
 - **SEVO**: **SEVO**flurane maintenance; 20 couples=40 patients
 - **PROSE**: donor **PROP**ofol recipient **SEVO**flurane; 20 couples=40 patients
- Primary outcome
 - KIM-1: Kidney injury molecule-1
 - NAG: N-Acetyl- β -D-Glucosaminidase
 - H-FABP: Heart Fatty Acid Binding Protein
- Secondary outcome measures
 - kidney biopsy specimen analysis, serum analysis, mGFR 3, 6 and 12m, DGF, PNF, graft loss, postoperative complications (all kinds), length of hospital stay, Acute rejection
- 2-year follow up

Nieuwenhuijs-Moeke GJ, Nieuwenhuijs VB, Seelen MAJ et al. Propofol-based anaesthesia versus sevoflurane-based anaesthesia for living donor kidney transplantation: results of the VAPOR-1 randomized controlled trial. *Br J Anaesth.* 2017 May 1;118(5):720-732




UMCG Transplantation
Comprehensive Transplant Center


Primary Outcome Measure




KIM-1



NAG



H-FABP




Nieuwenhuijs-Moeke GJ, Nieuwenhuijs VB, Seelen MAJ et al. Propofol-based anaesthesia versus sevoflurane-based anaesthesia for living donor kidney transplantation: results of the VAPOR-1 randomized controlled trial. *Br J Anaesth.* 2017 May 1;118(5):720-732



Secondary Outcomes Measures

Acute rejection



No ABMR, DSA –

T-cell mediated

- Cellular:
 - PROP 3
 - PROSE 1
- Vascular:
 - PROP 3
 - SEVO 2

Nieuwenhuijs-Moeke GJ, Nieuwenhuijs VB, Seelen MAJ et al. Propofol-based anaesthesia versus sevoflurane-based anaesthesia for living donor kidney transplantation: results of the VAPOR-1 randomized controlled trial. *Br J Anaesth.* 2017 May 1;118(5):720-732

In conclusion

- SEVO showed higher urinary KIM-1 and NAG levels in LDKT the 2nd day after transplantation. This was not reflected in inferior graft outcome
- A lower acute rejection rate was seen in the sevo groups.
- Acute rejection = multi-hit model
- An inflammatory environment due to parenchymal injury during transplantation makes the graft more prone to acute and chronic rejection



- Is anesthesia one of the keys to lock the door to rejection?



Nieuwenhuijs-Moeke GJ, Nieuwenhuijs VB, Seelen MAJ et al. Propofol-based anaesthesia versus sevoflurane-based anaesthesia for living donor kidney transplantation: results of the VAPOR-1 randomized controlled trial. *Br J Anaesth.* 2017 May 1;118(5):720-732



UMCG Transplantation
Comprehensive Transplant Center

Next step: VAPOR-2



UMCG Transplantation
Comprehensive Transplant Center


VAPOR-2

- International multicenter RCT
 - University Medical Center Groningen
 - Aarhus university Hospital
 - Fundagjo Puigvert Barcelona
 - Oslo University Hospital

- DBD and DCD donors

- 2 groups
 - PROP: PROPOfol-remifentanil
 - SEVO: SEVOflurane-remifentanil

- Inclusion started May 2017



UMCG Transplantation
Comprehensive Transplant Center

VAPOR-2

- Primary outcome:
 - DGF
 - 488 patients (red in DGF 30%)

- Secondary outcome:
 - graft and patient survival
 - PNF
 - AR
 - biochemical kidney function
 - look in to the mechanisms of protection/immunomodulation with anesthetic agents
 - Immunophenotyping (separate project VAPOR-3)
 - Transcriptomics/proteomics TDI Oxford



UMCG Transplantation
Comprehensive Transplant Center



www.vapor-2.org

NCT02727296



www.vapor-2.org

Thank you

